Contact

• workRoom 1701 QMC, E Floor East Block
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• andrew.prayle@nottingham.ac.uk

Biography

Andrew graduated from Nottingham in 2003 with a BMBS and entered clinical practice. He commenced the paediatric postgraduate training scheme in 2005. In 2009, he commenced a PhD in child health, and was awarded a NIHR Doctoral Research Fellowship in 2010, where he studied biomarkers of toxicity in children and adults with cystic fibrosis. Post PhD, after a further period of clinical practice he returned to research and holds a NIHR Academic Clinical Lecturer post in Child Health.

Expertise Summary

Clinical research studies: Andrew ran the CEFIT study (a cross sectional observational clinical study) and the CRITIC study (a randomised phase IV pharmacokinetic study). Andrew uses MWPharm for pharmaocokinetic modelling.

In the laboratory, Andrew measures biomarkers of kidney toxicity in urine samples and cultured kidney epithelial cells.

Andrew is the study co-ordinator of 3 pulmonary MRI studies (one in Ataxia telangiectasia (currently recruiting) and two in young children and infants (currently in setup). The goal of these separate but related studies is to identify MRI endpoints suitable for use in clinical trials.

Andrew has an interest in understanding how clinical trials influence research practice, and has ongoing projects in this area. Andrew is interested in applying machine learning to clinical problems.

Andrew teaches an informal seminar series on the R language for statistics within his division.

Research Summary

Andrew is currently working on identifying pulmonary endpoints for clinical trials, with the goal of improving the pulmonary health of children. During childhood the lungs develop and grow, and the… read more

Recent Publications

• SAFAVI, S., PRAYLE, A.P., HALL, I.P. and PARMAR, J., 2017. Azithromycin for treatment of bronchiolitis obliterans syndrome in adult lung transplant recipients Cochrane Database of Systematic Reviews. 2017(9),
• STEWART E, PRAYLE AP, TOOKE A, PASALODOS S, SURI M, BUSH A and BHATT JM, 2016. Growth and nutrition in children with ataxia telangiectasia. Archives of disease in childhood. 101(12), 1137-1141
• HURLEY MN, , PRAYLE AP and FLUME P, 2015. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric respiratory reviews. 16(4), 246-8
• HURLEY MN, PRAYLE AP and FLUME P, 2015. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. The Cochrane database of systematic reviews. CD009730

• View all publications

Current Research

Andrew is currently working on identifying pulmonary endpoints for clinical trials, with the goal of improving the pulmonary health of children. During childhood the lungs develop and grow, and the single biggest predictor of your lifespan as an adult is your lung function. Therefore, it is important to optimize the health of the lungs in childhood. In recent years, it has become clear that our current tools for assessing lung health, particularly in young children, are either too invasive for clinical research, or to insensitive to subtle changes in lung function. Andrew is therefore running a number of projects to investigate the application of pulmonary MRI in children as endpoints in clinical trials.

• SAFAVI, S., PRAYLE, A.P., HALL, I.P. and PARMAR, J., 2017. Azithromycin for treatment of bronchiolitis obliterans syndrome in adult lung transplant recipients Cochrane Database of Systematic Reviews. 2017(9),
• STEWART E, PRAYLE AP, TOOKE A, PASALODOS S, SURI M, BUSH A and BHATT JM, 2016. Growth and nutrition in children with ataxia telangiectasia. Archives of disease in childhood. 101(12), 1137-1141
• HURLEY MN, , PRAYLE AP and FLUME P, 2015. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric respiratory reviews. 16(4), 246-8
• HURLEY MN, PRAYLE AP and FLUME P, 2015. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. The Cochrane database of systematic reviews. CD009730
• PRAYLE AP, JAIN K, TOUW DJ, KOCH BC, KNOX AJ, WATSON A and SMYTH AR, 2015. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 15(4), 510-7
• HURLEY, MATTHEW N., MCKEEVER, TRICIA M., PRAYLE, ANDREW P., FOGARTY, ANDREW W. and SMYTH, ALAN R., 2014. Rate of improvement of CF life expectancy exceeds that of general population-Observational death registration study JOURNAL OF CYSTIC FIBROSIS. 13(4), 410-415
• PRAYLE, A., JAIN, K., WATSON, A. and SMYTH, A. R., 2013. ARE MORNING DOSES OF INTRAVENOUS TOBRAMYCIN LESS NEPHROTOXIC THAN EVENING? EVIDENCE FROM URINARY BIOMARKERS IN THE CRITIC STUDY PEDIATRIC PULMONOLOGY. 48, 299-299
• JOHN, MICHELLE, HUSSAIN, SAMIA, PRAYLE, ANDREW, SIMMS, REBECCA, COCKCROFT, JOHN R. and BOLTON, CHARLOTTE E., 2013. Target renal damage: the microvascular associations of increased aortic stiffness in patients with COPD RESPIRATORY RESEARCH. 14,
• JAIN, K., PRAYLE, A., MCCULLOCH, T. A., POPE, M., SYMONDS, M. and SMYTH, A. R., 2013. GENE EXPRESSION OF CFTR AND RENAL ENDOCYTIC RECEPTORS IS NOT ALTERED IN THE KIDNEYS OF YOUNG PIGLETS WITH CYSTIC FIBROSIS PEDIATRIC PULMONOLOGY. 48, 271-271
• PRAYLE, ANDREW P. and SMYTH, ALAN R., 2013. From pipeline to patient: new developments in cystic fibrosis therapeutics EXPERT OPINION ON PHARMACOTHERAPY. 14(3), 323-329
• MODI, NEENA, CLARK, HOWARD, WOLFE, INGRID, COSTELLO, ANTHONY and BUDGE, HELEN, 2013. A healthy nation: strengthening child health research in the UK LANCET. 381(9860), 73-87
• PRAYLE, A., 2013. Homeostasis and the Respiratory System
• PRAYLE, A. and MIGHTEN, J., 2013. Pharmacology and the Respiratory System
• HURLEY, M N, PRAYLE, A P and SMYTH, A R, 2012. Delayed publication of clinical trials in cystic fibrosis. Journal of Cystic Fibrosis. 11(1), 14-17
• PRAYLE, A.P., HURLEY, M.N. and SMYTH, A.R., 2012. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study BMJ. 344(7838), d7373
• HURLEY, MATTHEW N. and PRAYLE, ANDREW P., 2012. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis PAEDIATRIC RESPIRATORY REVIEWS. 13(3), 160-161
• PRAYLE, ANDREW, ATKINSON, MARIA and SMYTH, ALAN, 2011. Pneumonia in the developed world. Paediatric respiratory reviews. 12(1), 60-9
• MCCULLOCH T, PRAYLE A, LUNN A and WATSON AR, 2011. Karyomegalic-Like Nephropathy, Ewing's Sarcoma And Ifosfamide Therapy. Pediatric Nephrology (Berlin, Germany). 26(7), 1163-6
• MCCULLOCH, TOM, PRAYLE, ANDREW, LUNN, ANDY and WATSON, ALAN R., 2011. Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy PEDIATRIC NEPHROLOGY. 26(7), 1163-1166
• LO, D. K. H., HURLEY, M. H., PRAYLE, A. and SMYTH, A. R., 2011. A UK REGISTRY STUDY OF PROPHYLACTIC ANTIBIOTIC USE FOR STAPHYLOCOCCUS AUREUS IN CHILDREN WITH CYSTIC FIBROSIS THORAX. 66, A163-A163
• PRAYLE, ANDREW, WATSON, ALAN, FORTNUM, HEATHER and SMYTH, ALAN, 2010. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 65(7), 654-8
• PRAYLE, A.P., HURLEY, M.N. and SMYTH, A.R., 2010. Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis Cochrane Database of Systematic Reviews. 2010(11), 1-18
• PRAYLE A and SMYTH AR, 2010. Aminoglycoside Use In Cystic Fibrosis: Therapeutic Strategies And Toxicity. Current Opinion In Pulmonary Medicine. 16(6), 604-10
• PRAYLE, ANDREW, WATSON, ALAN, FORTNUM, HEATHER and SMYTH, ALAN, 2010. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis THORAX. 65(7), 654-658
• PRAYLE, AP, POINTON, K, MANHIRE, AR, BALDWIN, DR and RICHARDSON, CM, 2004. Are patients adequately assessed prior to percutaneous lung biopsy? THORAX. 59(1), 64-64